Integral Molecular is a research-driven biotechnology company creating innovative technologies and therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes.

January 7, 2021

Integral Molecular and Optimeos Partner to Deliver Long-acting Therapeutic Antibodies Using Nanoparticle Formulation Technology

PHILADELPHIA — Integral Molecular and Optimeos Life Sciences have partnered to develop antibody therapeutics using long-acting, sustained delivery formulations that will improve patient care and quality […]
November 24, 2020

Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2

PHILADELPHIA – Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces fully optimized, high-affinity lead monoclonal antibodies (MAbs) against Claudin 18.2 (CLDN18.2), a […]
November 19, 2020

Integral Molecular Partners with China’s Leading Preclinical CRO JOINN for Comprehensive Specificity Testing of Antibodies and CAR-T Therapeutics

PHILADELPHIA – JOINN Laboratories, China’s leading preclinical contract research organization (CRO), has partnered with Integral Molecular to provide researchers in China with rapid antibody specificity testing […]
October 15, 2020
MPS/Lipo Image

Live Tutorial: 6 Steps to Success in Discovering Monoclonal Antibodies Against Multipass Membrane Proteins

Join us for a live interactive tutorial on October 29, 2020 to learn more about using our Membrane Protein Solutions. Integral Molecular has a 95% success […]
October 13, 2020

Totient Leverages Integral Molecular’s Membrane Proteome Array to Advance Cancer Therapeutic Discovery

PHILADELPHIA – Integral Molecular and Totient announce a partnership leveraging Integral Molecular’s Membrane Proteome Array (MPA) target identification technology to advance the discovery of antibodies for […]
September 18, 2020

Integral Molecular Awarded Grant from the Commonwealth of Pennsylvania to Advance COVID-19 Research

PHILADELPHIA – Integral Molecular has been awarded $521,723 from the Commonwealth of Pennsylvania to leverage its technologies in the global fight against COVID-19. Integral Molecular is […]
September 16, 2020

Integral Molecular & Fierce Bio Present: De-risk Antibody and CAR-T Safety by Identifying Off-target Specificity Webinar

The long-held assumption that antibodies are exquisitely specific is being re-examined since 25% of monoclonal antibodies (MAbs) show polyspecificity and bind unintended targets. This Fierce webinar […]
September 10, 2020

Humanized Chicken Antibody Technology to Drive Next Generation of Integral Molecular’s MPS Antibody Discovery Platform

PHILADELPHIA – Integral Molecular announces the development of Humanized Chicken Antibody Technology (hCAT) and the incorporation of hCAT into the company’s industry-leading MPS antibody discovery platform […]
August 25, 2020

Science Center to Honor Leaders of Innovation Community at Annual Nucleus Awards

PHILADELPHIA–(August 20, 2020) – The University City Science Center will recognize three local leaders during its annual Nucleus Awards event on September 22, 2020, presented by […]
July 13, 2020

Integral Molecular Expands its Reporter Virus Technology to Enable Broad Testing for Coronavirus Protection Against Emerging Strains Including D614G

PHILADELPHIA – Integral Molecular has launched an expanded panel of SARS-CoV-2 Reporter Virus Particles (RVP), which includes spike protein variants such as D614G and spike protein […]
June 10, 2020

Integral Molecular Provides Rapid Safety Testing of COVID-19 Antibody Therapeutics with its Membrane Proteome Array Technology

PHILADELPHIA – Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for […]
April 30, 2020

Integral Molecular Develops Test for Neutralizing Antibodies in COVID-19 Patients and Clinical Trials

PHILADELPHIA – Integral Molecular announces the launch of SARS-CoV-2 Reporter Virus Particles (RVPs) to test patients for the presence of neutralizing antibodies, determine the effectiveness of […]
April 21, 2020

Integral Molecular Receives NIAID Award to Combat COVID-19

PHILADELPHIA – The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to enable the application of Integral Molecular’s technology platforms […]
March 9, 2020

Integral Molecular Accelerates Coronavirus Vaccine Research

PHILADELPHIA –Integral Molecular announces the mobilization of two of its key technology platforms to aid in the discovery of vaccines and therapeutics against the novel coronavirus […]
February 12, 2020

Integral Molecular Launches ReadyMap Services for Rapid, Conformational Epitope Mapping

PHILADELPHIA –Integral Molecular, the industry leader in the discovery and characterization of antibodies against membrane proteins, announces the launch of ReadyMap services, an expansion of its […]
January 8, 2020

Integral Molecular Announces Preclinical P2X7 Antibody Assets for Autoimmune Disorders

PHILADELPHIA – Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces lead monoclonal antibodies (MAbs) against P2X7, a structurally complex ion channel that […]
November 14, 2019

Integral Molecular to Advance Vaccine Discovery with NIH Contract for $5.5M

PHILADELPHIA – (PR NEWSWIRE) – The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular a contract (75N93019C00073) which will provide up to […]
October 18, 2019

Philadelphia’s Integral Molecular Opens New Research Center in Response to Upsurge in Antibody Discovery Partnerships

PHILADELPHIA – (PR NEWSWIRE) – Integral Molecular, the industry leader in membrane protein solutions, has expanded its research facility to a second location to accommodate an […]
September 26, 2019

Integral Molecular Selected as the First Industry Partner in The Wistar Institute’s Biomedical Research Technician Apprenticeship

PHILADELPHIA ¬ Sept. 26, 2019 — Integral Molecular, Inc. has been selected by The Wistar Institute, a global leader in cancer, immunology and infectious disease research […]
August 8, 2019

Integral Molecular and Penn Medicine Collaborate on Autoimmune Encephalitis Target Discovery

Integral Molecular is announcing a new collaboration with the Perelman School of Medicine at the University of Pennsylvania (Penn). Integral Molecular and Penn will work together […]